Understanding Organoid Morphology: A Study To Assess Organoid Size And Cell Count From 3D Image Analysis

This content is brought to you by Molecular Devices, a Danaher Operating Company.

In the pharmaceutical industry, compound library screens using 2D monolayer cancer cell lines are a common practice to identify molecules with therapeutic potential. This involves generating and testing multiple analogues and modified derivatives before any candidates can progress to clinical trials. However, this lengthy and costly process has a poor success rate, particularly in oncology, where the success rate is less than 5%. One of the main reasons for this low success rate is the inability of current preclinical cell-based assays to predict clinical efficacy. Recent advancements have shown that 3D patient-derived organoids (PDOs) offer improved predictive power and hold the potential to replace 2D assays in drug discovery. Despite their promise, the utility of PDOs is currently limited by the lack of standardized assays that are proven to be applicable in the pharmaceutical industry.

Molecular Devices has addressed these challenges by developing a unique and patented industrial bioprocess for the large-scale expansion of PDOs. This proprietary bioprocess generates highly standardized PDOs at scale and enables their use in applications such as high-throughput screening for drug discovery.

Discover how this innovation has the potential to significantly improve the efficiency and success rate of drug discovery processes, particularly in oncology.